New stem cell therapy shows 'promising' results for treating hair loss in preclinical trials
A recent study analyzed the effect of injecting mice's skin with stem cells from human fat — "adipose-derived stem cells (ASCs)" — as a means of treating androgenetic alopecia (AGA), more commonly known as male- or female-pattern hair loss.
The team found that male mice achieved the best hair regrowth after three weeks when they received low-dose ASCs, combined with an energy-boosting molecule called adenosine triphosphate (ATP).
Hairstylists And Medical Expert Confirm Temporary Hair Loss Affecting Ozempic Users
Low-dose and high-dose ASC treatments along with ATP led to no hair regrowth improvement in females, but medium-dose ASC plus ATP led to greater regrowth.
The researchers concluded that hair regrowth was improved in "all experimental groups" where male mice received stem cell solutions supplemented with ATP.
Read On The Fox News App
The findings were published in the journal Stem Cell Research & Therapy.
Lead study author Dr. Eduardo López Bran — dermatologist and professor at The Complutense University of Madrid — shared his expectations for the study in an interview with Fox News Digital.
This Daily Beauty Routine Could Be Ruining Your Hair, Experts Warn
"We expected good results, but not such a high level of success," he said. "We're talking about a very high degree of hair regrowth in both male and female mice."
With appropriate doses, the researchers achieved "very high percentages" of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair.
"These results demonstrate that advanced therapies may represent a new therapeutic approach for many diseases for which no effective treatments are currently available," Bran went on.
"Achieving such promising results in the preclinical phase with a completely novel approach to androgenetic alopecia — one that avoids chronic treatment and is also safe — is a significant scientific milestone."
The main limitation of the study was the thinness of mouse skin, Bran noted, which "posed a challenge in administering the therapy."
"This required the development of protocols to minimize experimental variability, and will be a key factor when studies in humans begin," he said.
These new findings should be "interpreted with caution and scientific rigor," Bran cautioned.
"Although the results in mice represent significant progress, it is also true that it is essential to wait for clinical benefits in humans to be confirmed."
Click Here To Sign Up For Our Health Newsletter
The researcher encouraged those with androgenetic alopecia to continue consulting with their dermatologists and to follow prescribed treatments as research develops.
"It is important to remain hopeful. Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits," Bran added.
Looking ahead to human clinical trials, researchers are "actively working" on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia, the researcher noted.
"If everything progresses as expected, the most optimistic timeline points to the treatment becoming available in approximately five years," he said.
In a separate interview with Fox News Digital, Dr. Brendan Camp, M.D., a New York-based dermatologist who was not involved in the study, commented on the potential for this method.
"While not commercially available, this study suggests that injection of stem cells supplemented with ATP into scalp skin could potentially encourage hair regrowth in individuals with androgenetic alopecia," he reiterated.
For more Health articles, visit www.foxnews.com/health.
"This study is small, and more research is needed on this method as a potential treatment option for androgenetic alopecia."
Until then, Camp encourages people to focus on currently available and "well-studied" treatments to address hair loss, and to visit a board-certified dermatologist for evaluation.Original article source: New stem cell therapy shows 'promising' results for treating hair loss in preclinical trials
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Eli Lilly raising GLP-1 prices abroad raises more questions about US pricing: BofA analyst
Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing in peer developed nations. The effort, known as Most Favored Nations pricing, has been a goal of Trump's since his first term. He has doubled down on the efforts this year, giving pharma companies 60 days to implement changes in pricing in what he deems "freeloading" nations. The US drug economy differs from European and other developed nations, which rely on the government to negotiate prices with drugmakers, resulting in lower prices globally. "While we agree that the costs for breakthrough medicines should be more fairly shared across developed countries, we must also address the underlying structural issues in the US that have contributed to high drug prices. The US system is complex and opaque," Lilly said in a statement Thursday. The stock was up 1% in trading Friday. Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America Securities research analyst Tim Anderson questioned who would actually be impacted by the raised prices. "LLY has announced it will raise GLP-1 pricing in the UK by a healthy margin (a doubling of price, but it's unclear to whom this higher price realistically applies). It expects to do something similar in other European countries (but worth appreciating: in most European markets, there aren't price agreements in place between GLP-1 manufacturers and governments, meaning these are out-of-pocket spending markets)," Anderson wrote. Ultimately, whether or not the move results in lower US prices remains a question, though Anderson believes it likely will not. "Does this mean it will actually cut the price on the GLP-1s in the US (and on other medicines)? To us, the answer is quite likely no, or at least, not in a way that creates P&L [profit and loss planning ] risk," he wrote. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Andrew Flintoff backs campaign to increase helipads at hospitals
Andrew 'Freddie' Flintoff has backed a campaign to help more hospitals get helipads after his own experience of medical air support following his car crash at a Top Gear test track. In December 2022, Flintoff sustained severe injuries while filming at the Dunsfold Aerodrome in Surrey for an episode of BBC show Top Gear. The former international cricketer was airlifted to St George's Hospital in Tooting – a major trauma centre. The helipad at the hospital was funded by a campaign with the Helicopter Emergency Landing Pads (Help) Appeal. As he backed the campaign, Flintoff said: 'When I was airlifted, that helipad wasn't just a safe spot to land on the hospital roof, it was a vital step in giving me a second chance as I had immediate access to the specialist care which helped saved my life. 'As every cricket pitch has a wicket, every hospital that needs one should have a helipad.' The Help Appeal said that there have been 30,000 landings on the 32 NHS hospital helipads funded by the charity across the country. It has also funded 23 major upgrades at other hospital helipads. The charity is aiming to fund 40 new and upgraded helipads. Robert Bertram, chief executive of the Help Appeal, said: 'We are incredibly grateful to have Freddie's support, especially knowing that his life was saved thanks, in part, to a Help Appeal-funded helipad. His story highlights exactly why the charity's work is so vital – seconds count in a medical emergency and that helipad made all the difference. 'Freddie's backing brings invaluable awareness to the importance of rapid access to emergency care for everyone, everywhere.' Sir Keith Porter, emeritus professor of clinical traumatology at the University of Birmingham, said the charity plays a 'crucial part' in getting patients to the right hospital at the right time. He added: 'Helicopter Emergency Medical Services have the ability to deliver critical care teams at or close to the side of a patient and then to transport them to the most appropriate hospital for their clinical needs, in the case of injury, usually a major trauma centre. 'Minutes count, particularly for patients with life-threatening bleeding, where the extra journey time can make the difference between life and death. 'The Help Appeal, by funding on-site helipads, helps facilitate the prompt delivery of patients directly into the emergency department with a trolley-push from the landing site.' Flintoff also recently visited the NHS staff who cared for him after the accident at St George's Hospital. He praised health workers in the NHS as 'superheroes' and described the aftermath of the crash as the 'the lowest I've ever been'. The 47-year-old praised the 'expertise, love and compassion' shown by staff at the hospital during his time of need. During a documentary about the accident, Flintoff described how he used the split-second decision-making from his cricketing days to try to reduce the impact of the crash. He said he was 'pulled face-down on the runway' for about 50 metres under the car. The former England star said he thought he had died in the accident. For months after the crash, Flintoff disappeared from public view and would leave his house only for medical appointments His recovery has been documented in a documentary, Flintoff, streamed on Disney+.
Yahoo
3 hours ago
- Yahoo
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based on part 1 of the ESSENCE trial, in which Wegovy® demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo. The clinical data from ESSENCE showed that at week 72, 36.8% of people treated with Wegovy® achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% treated with placebo. 62.9% of people treated with Wegovy® achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% treated with placebo. 'Wegovy® is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide,' said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development, at Novo Nordisk. 'MASH represents a significant health burden, with one in three people with overweight or obesity worldwide affected. In the US alone, around 22 million people are estimated to live with MASH. With the approval of Wegovy® for MASH, we provide a new treatment to people living with MASH that not only halts the disease activity but helps reverse the damage caused to the liver.' As of today, Wegovy® is available in the US for the treatment for MASH. About MASH Metabolic dysfunction-associated steatohepatitis (MASH) is a serious, progressive, metabolic disease affecting the liver, which can be fatal if not properly managed. More than 250 million people live with MASH and the number of individuals in advanced stages of the disease is expected to double by 2030. Of those who are currently overweight or living with obesity, more than one in three are also living with MASH. People living with MASH often experience few or no specific symptoms in the early stages of the disease, which often results in delayed diagnosis. The risk of progression to advanced liver disease, including liver cancer, is higher in people living with MASH than in the general population. About the ESSENCE trial ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg in adults with metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis (stage 2 or 3). ESSENCE is a two-part trial where 1,200 planned participants were randomised 2:1 to receive semaglutide 2.4 mg or placebo, on top of standard of care for 240 weeks. In part 1, the objective was to demonstrate that treatment with semaglutide 2.4 mg improves liver histology at 72 weeks based on biopsy sampling from the first 800 randomised patients. In part 2, the objective is to demonstrate that treatment with semaglutide 2.4 mg lowers the risk of liver-related clinical events compared to placebo in adults with MASH and moderate to advanced liver fibrosis at 240 weeks. Based on part 1 of the ESSENCE trial, Novo Nordisk has also filed for regulatory approval in the EU in February 2025, with a subsequent filing in Japan in May 2025. Part 2 of the ESSENCE trial is expected to read out in 2029. About Wegovy® (semaglutide 2.4 mg) The FDA initially approved Wegovy® in 2021 with a reduced calorie meal plan and increased physical activity to help adults with obesity, or adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off. The indication was expanded in 2022 to include children aged 12 years and older with obesity. In 2024, Wegovy® was approved to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight. Today, the FDA granted accelerated approval for Wegovy® for a new patient population for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information: Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode +45 3075 5956 jrde@ Sina Meyer +45 3079 6656 azey@ Frederik Taylor Pitter (US) +1 609 613 0568 fptr@ Max Ung +45 3077 6414 mxun@ Publication of inside information pursuant to Market Abuse Regulation, Article 17. Attachment CA250815-MASH-US-label-update
